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Abstract
Objective:  Evaluate  the  ability  of  clonidine  to  reduce  pulmonary  arterial  pressure  in  patients
with pulmonary  hypertension  undergoing  heart  surgery,  either  by  reducing  the  pressure  values
from  the  direct  measurement  of  pulmonary  arterial  pressure  or  by  reducing  or  eliminating  the
need  for  intraoperative  dobutamine  and  nitroprusside.
Method:  Randomized,  double-blind,  placebo-controlled,  comparative  study  conducted  in  30
patients  with  pulmonary  arterial  hypertension  type  2  undergoing  cardiac  surgery.  Mean  pul-
monary  arterial  pressure  and  dosage  of  dobutamine  and  sodium  nitroprusside  were  assessed
four  times:  before  intravenous  administration  of  clonidine  (2  g/kg)  or  placebo  (T0),  30  min
after  tested  treatment  and  before  cardiopulmonary  bypass  (T1),  immediately  after  CPB  (T2),
10  min  after  protamine  injection  (T3).
Results: There  were  no  signiﬁcant  differences  regarding  mean  pulmonary  arterial  pressure  at
any  time  of  evaluation.  There  was  no  signiﬁcant  difference  between  groups  regarding  other
variables,  such  as  mean  systemic  arterial  pressure,  heart  rate,  total  dose  of  dobutamine,  total
dose  of  sodium  nitroprusside,  and  need  for  fentanyl.
Conclusion:  Data  analysis  from  patients  included  in  this  study  allows  us  to  conclude  that  intra-
venous clonidine  (2  g/kg)  was  not  able  to  reduce  the  mean  pulmonary  arterial  pressure  in
patients  with  pulmonary  hypertension  in  group  2  (pulmonary  venous  hypertension),  undergoing
heart  surgery,  or  reduce  or  eliminate  the  need  for  intraoperative  administration  of  dobutamine
and  sodium  nitroprusside.
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Introduction
Pulmonary  hypertension  (PH)  is  a  chronic  disease  deﬁned
by high  mean  pulmonary  arterial  pressure  above  25  mmHg
at rest  or  30  mmHg  on  exertion.  Due  to  its  varied  etiology,
PH is  associated  with  three  major  deleterious  phenomena:
vascular remodeling,  hypoxic  vasoconstriction,  and  in  situ
thrombosis. PH  is  difﬁcult  to  control  and  evolves  with  hypox-
emia, increased  resistance  to  ejection  of  blood  by  the  right
ventricle (RV),  RV  failure,  and  death.1
PH  is  classiﬁed  into  ﬁve  groups:  (I)  pulmonary  arterial
hypertension (includes  the  idiopathic  form);  (II)  pulmonary
hypertension associated  with  left  heart  diseases;  (III)  pul-
monary hypertension  associated  with  respiratory  disease
and/or hypoxemia;  (IV)  pulmonary  hypertension  due  to
chronic thrombotic  and/or  embolic  disease;  and  (V)  miscel-
laneous group.1
PH  is  most  often  found  in  group  II  patients,  as  a  result
of left  ventricle  (LV)  failure  associated  with  other  common
heart disease  progression,  such  as  valvular  heart  disease
and coronary  artery  disease.2 Myocardial  failure  makes  the
LV unable  to  eject  blood  into  the  systemic  circulation  that
reaches the  left  heart  through  the  pulmonary  veins.  The
high pressure  of  the  pulmonary  venous  bed  is  transmitted
backward to  the  arterial  system.  For  no  other  reason,  PH
of group  II  is  referred  to  as  pulmonary  venous  hypertension
(PVH).3
Anesthesia  in  these  patients  is  an  enormous  challenge
because it  is  necessary  to  control  both  the  ventricular
disease and  pulmonary  hypertension.  To  face  it,  various
combinations of  drugs  are  used,  including  the  association
of inotropic  dobutamine  (DBT)  and  the  vasodilator  sodium
nitroprusside (NTP),  which  is  one  of  the  more  frequently
used. However,  to  be  effective,  it  is  often  necessary  to  use
high doses  of  these  agents.  Undesirable  effects  may  arise,
such as  tachycardia  with  the  use  of  dobutamine  or  increased
intracranial pressure,  coronary  steal,  intrapulmonary  shunt,
and metabolic  acidosis  with  sodium  nitroprusside.4 Thus,
the pharmacological  options  available  are  not  without  side
effects, which  justify  the  interest  for  new  therapeutic
options.
Clonidine, a  2-adrenergic,  imidazole  agonist,  was
introduced into  clinical  practice  in  the  early  1960s.  This
drug was  ﬁrst  proposed  as  a  nasal  decongestant,  but  soon
its systemic  effects  became  known,  such  as  hypotension,
bradycardia, and  sedation.5
Due  to  the  hypotensive  effect  of  clonidine,  which
decreases the  exocytosis  of  noradrenaline  in  the  synaptic
cleft, both  in  the  central  and  peripheral  nervous  system,6 it
is now  prescribed  for  hypertension  management.  In  recent
decades, this  agent  was  studied  as  an  adjunct  to  anes-
thesia. The  advantages  of  clonidine  in  this  context  were
recognized and  its  use  spread  also  in  the  ﬁeld  of  anesthe-
sia in  cardiac  surgery.  Among  other  beneﬁts,  clonidine  is
known to  reduce  the  need  for  opioids  intra-  and  postopera-
tively, which  allows  early  tracheal  extubation  and  shortens
the duration  of  mechanical  ventilation;  hemodynamic  stabil-
ity at  lower  levels  of  circulating  catecholamines;  increased
diuresis due  to  inhibition  of  the  release  of  antidiuretic  hor-
mone (ADH);  and  release  of  atrial  natriuretic  factor.6
The  presence  of  2-adrenergic  receptors  in  lung  tissues7--9
and  its  central  hypotensive  action  seem  to  indicate  that
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lonidine  may  also  be  useful  for  treating  PH  patients  under-
oing heart  surgery.
ethods
fter  approval  by  the  Ethics  Committee  of  the  Hospital  São
aulo (Unifesp)  and  Hospital  Beneﬁcência  Portuguesa  (São
aulo-SP) and  obtaining  signed  informed  consent  from  all
articipants, 30  patients  of  both  sexes,  physical  status  ASA  II
r III,  aged  between  18  and  80  years,  with  pulmonary  hyper-
ension secondary  to  left  heart  disease  were  enrolled  in  the
tudy between  January  2009  and  December  2010.  Due  to
he expiration  date  of  the  batch  of  drugs,  one  patient  was
xcluded from  the  study.
Patients  underwent  cardiac  surgery  with  cardiopul-
onary bypass  for  valvular  correction  or  myocardial
evascularization.
The diagnosis  of  pulmonary  hypertension  was  previously
onﬁrmed by  right  heart  catheterization  and  deﬁned  by
ean pulmonary  arterial  pressure  greater  than  25  mmHg  at
est.
After fasting  for  8  h,  the  patients  were  taken  to  the
perating room  without  receiving  pre-medication.  In  the
perating room,  they  were  monitored  with  electrocar-
ioscope on  DII  and  V5  derivations  and,  pulse  oximetry,
nd for  noninvasive  blood  pressure.  All  patients  under-
ent venipuncture  and  intravenous  administration  of  3  mg
idazolam. After  this  step,  left  or  right  radial  artery  was
annulated with  a  catheter  caliber  20G  for  direct  blood
ressure measurement  and  blood  sample  collection  for  lab-
ratory testing.
Anesthesia consisted  of  preoxygenation  for  3  min,  fol-
owed by  administration  of  fentanyl  (10  g/kg),  etomidate
0.4 mg/kg),  pancuronium  (0.1  mg/kg),  lidocaine  (1  mg/kg),
acemask ventilation  with  100%  oxygen  for  5--7  min,  fol-
owed by  intubation  and  maintenance  with  1%  isoﬂurane
n oxygen  and  air  (1:1).  After  tracheal  intubation,  moni-
oring was  complemented  by  analysis  of  anesthetic  gases,
apnometry, and  capnography.
Intraoperatively,  we  try  to  maintain  mean  arterial  pres-
ure between  50  and  80  mmHg  with  additional  doses  of
entanyl (5  g/kg)  and,  if  necessary,  sodium  nitroprusside.
ases of  hypotension  were  treated  according  to  the  eti-
logy, either  with  volume  management  or  with  inotropic,
hronotropic or  vasopressor  agents.
After  sternotomy  and  retractor  placement,  an  18G  teﬂon
atheter was  placed  under  direct  vision  into  the  pulmonary
rtery to  allow  direct  measurement  of  pulmonary  artery
ressure.
During cardiopulmonary  bypass,  in  order  to  keep  patients
nder hypnosis  and  immobility,  midazolam  (0.3  mg/kg)  and
ancuronium (0.1  mg/kg)  were  administered  again.  At  the
nd of  this  stage,  all  patients  were  treated  with  dobut-
mine (5--10  g/kg/min),  in  order  to  ensure  hemodynamic
tability (compensating  for  impaired  myocardial  contractil-
ty by  ischemia-reperfusion  and  heart  manipulation  during
ardiopulmonary bypass).
Categorical  variables,  such  as  age,  weight,  gender,  and
iagnosis were  evaluated.  Mean  arterial  pressure  (MAP),
eart rate  (HR),  mean  pulmonary  artery  pressure  (MPAP),
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There was  signiﬁcant  change  in  HR  at  the  assessment  times
in both  groups  (p  =  0.036).  T0  did  not  differ  signiﬁcantly  from
T1 (p  =  0.059),  T2  (p  =  0.149),  and  T3  (p  =  0.273).  T1  differed
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Figure  1  Evolution  of  MAP.
0,00
20,00
40,00
60,00
80,00
100,00
120,00
140,00
H
R
 (b
pm
)
T0 T1 T2 T32  
nd  doses  of  sodium  nitroprusside,  dobutamine,  and  fen-
anyl were  recorded  at  the  following  times:
After  sternum  opening  and  retractor  placement,  before
clonidine  (T0).
Thirty minutes  after  clonidine  administration  (T1).
At  the  end  of  cardiopulmonary  bypass  (T2).
Ten minutes  after  protamine  (T3).
Immediately  after  the  ﬁrst  measurements  (T0),  a  coded
olution (clonidine  2  g/kg  or  placebo)  was  administered  to
very patient  using  slow  intravenous  injection.  The  tested
olution decoding  was  made  just  before  data  analysis,  as
xplained in  the  annex.
Sample size  calculation  was  made  considering  the
ypothesis of  15%  decrease  in  pulmonary  pressure  with  a
tandard deviation  of  5.5.  To  obtain  a  test  with  a  signiﬁcance
evel of  5%  and  80%  power,  14  patients  were  required  for  the
reatment group  and  14  for  the  placebo  group.  Calculations
ere made  with  BioEstat  3.0.
In  principle,  all  variables  were  analyzed  descriptively.
or quantitative  variables,  the  analysis  was  performed  by
bserving the  minimum  and  maximum  values  and  calculating
verages, standard  deviations,  and  medians.  For  qualitative
ariables, absolute  and  relative  frequencies  were  calcu-
ated.
To compare  the  means  of  both  groups,  the  Student’s  t-
est was  used.  When  the  normality  assumption  was  rejected,
he nonparametric  Mann--Whitney  test  was  used.10
To  test  homogeneity  between  proportions,  chi-square
est or  Fisher’s  exact  test  was  used  (when  expected  fre-
uencies were  less  than  5).10
To  analyze  the  groups’  behavior  considering  the  condi-
ions studied,  analysis  of  variance  with  repeated  measures
as used,11 which  consists  of  adjusting  a  multivariate  linear
odel from  which  the  following  hypotheses  were  tested:
H01:  the  average  response  proﬁles  corresponding  to  the
groups  are  parallel,  i.e.,  there  is  no  interaction  between
group  factor  and  valuation  condition  factor  (T0,  T1,  T2  and
T3).
H02:  the  average  response  proﬁles  are  coincident;  i.e.,
there  is  no  group  factor  effect  group.
H03: the  average  response  proﬁles  are  parallel  to  the
abscissas’  axis;  i.e.,  there  is  no  evaluation  condition  factor
effect.
When  the  assumption  of  data  normality  was  rejected,
onparametric Mann--Whitney  test  (comparison  of  both
roups at  each  time)  and  Friedman’s  test  (comparison  of
imes in  each  group)  were  applied.10
The  signiﬁcance  level  of  5%  was  used  for  the  tests.
esults
wenty-nine  patients,  aged  between  27  and  75  years  (mean
5.10 years,  with  a  standard  deviation  of  10.54  years  and  a
edian of  56  years),  were  evaluated,  of  whom  17  were  male
58.6%) and  12  (41.4%)  female.  The  patients  were  divided
nto two  groups:  placebo  (n  =  14)  and  clonidine  (n  =  15).B.B.  João  et  al.
Table  1  shows  the  comparison  of  groups  regarding  cate-
orical variables,  and  it  was  noted  that  the  groups  did  not
iffer signiﬁcantly  in  age,  weight,  sex,  and  diagnosis.
Table  2  shows  the  comparison  of  groups  regarding  surgical
ariables.
Table 3  shows  the  comparison  of  groups  regarding  base-
ine pressure  measurement,  and  it  was  noted  that  the  groups
id not  differ  signiﬁcantly  with  respect  to  baseline  pressure.
Table  4  shows  the  evolution  of  variables  over  the  time
eriods studied.  Student’s  t-test  evaluation  showed  that  the
roups did  not  differ  signiﬁcantly  at  time  T0  regarding  MAP
p =  0.779).
In  the  analysis  of  variance  with  repeated  measures,  there
as no  signiﬁcant  difference  between  groups  with  respect
o behavior  (p  =  0.703)  and  the  average  at  each  time  point
p =  0.051).  There  was  signiﬁcant  change  in  MAP  at  the
valuated times  in  both  groups  (p  <  0.001).  T0  differed  sig-
iﬁcantly from  T1  (p  =  0.001)  and  did  not  differ  from  T2
p =  0.085)  and  T3  (p  =  0.168).  T1  differed  signiﬁcantly  from
2 (p  <  0.001)  and  T3  (p  = 0.022).  T2  differed  signiﬁcantly
rom T3  (p  =  0.001)  (Fig.  1).
With  the  use  of  Student’s  t-test,  we  found  no  signiﬁcant
ifference between  groups  at  T0  regarding  HR  (p  =  0.865)
Table 5).
Analysis of  variance  with  repeated  measures  revealed
o signiﬁcant  difference  between  groups  regarding  behavior
p =  0.321)  and  mean  for  each  assessment  time  (p  =  0.979).Times
Clonidine Placebo
Figure  2  Evolution  of  HR.
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Table  1  Categorical  variables.
Variable  Category  Group  p
Clonidine  (n  =  15)  Placebo  (n  =  14)
Age  52.4  +  11.7  57.9  +  8.6  0.167a
Weight  67.5  +  13.8  68.2  +  12.5  0.880a
Sex  Female  5  (33.3%)  7  (50.0%)  0.362b
Male  10  (66.7%) 7  (50.0%)
ASD/COI  0  (0.0%) 1 (7.1%)
DML  5  (33.3%) 5  (35.7%)
AS  1  (6.7%)  0  (0.0%)
Diagnosis SM  4  (26.7%)  3  (21.4%)  0.675c
MI  5  (33.3%)  2  (14.3%)
MI/COI  0  (0.0%)  1  (7.1%)
AR  0  (0.0%)  1  (7.1%)
AR/MI  0  (0.0%)  1  (7.1%)
ASD, atrial septal defect; COI, coronary insufﬁciency; DML, double mitral lesion; AS, aortic stenosis; MS, mitral stenosis; MI, mitral
insufﬁciency; AR, aortic regurgitation.
a Descriptive level of probability of Student’s t-test.
b Descriptive level of probability of the chi-square test.
c Descriptive level of probability of Fisher’s exact test.
Table  2  Surgical  variables  according  to  study  group.
Variable  Group  N  Mean  SD  Median  Min  Max  p
Anesthesia  Clonidine  15  258.33  35.32  255  210  345  0.173a
Time Placebo  14  236.79 47.17  240  125  315
Surgery Clonidine  15  203.27  22.11  200  170  245  0.609a
time  Placebo  14  196.86  40.92  197.5  95  270
Fluid Clonidina  15  796.67  221.57  900  150  950  0.752b
balance  Placebo  14  871.43  82.54  850  800  1000
Blood Clonidine  15  −50.00  269.26  −200  −250  550  0.292b
balance  Placebo  14  70.71  295.41  0  −200  480
Diuresis Clonidine  15  1000.00  602.38  1000  −700  2000  0.510b
Placebo  14  1122.00  293.68  1150  500  1600
itne
(
f
d
sa Descriptive level of probability of Student’s t-test.
b Descriptive level of probability of the nonparametric Mann--Wh
signiﬁcantly  from  T2  (p  =  0.015)  and  T3  (p  =  0.035).  T2  did
not differ  signiﬁcantly  from  T3  (p  =  0.188)  (Fig.  2).
Student’s t-test  revealed  that  the  groups  did  not  differ
signiﬁcantly at  T0  in  relation  to  MPAP  (p  =  0.068)  (Table  6).
Analysis of  variance  with  repeated  measures  revealed
no signiﬁcant  difference  between  groups  regarding  behavior
(p =  0.334)  and  mean  for  each  assessment  time  (p  =  0.223).
There was  signiﬁcant  change  in  MPAP  times  evaluated  in
both groups  (p  <  0.001).  T0  differed  signiﬁcantly  from  T1
e
w
Table  3  Baseline  pressure  according  to  study  group.
Variable  Group  N  Mean  
MPAP  Clonidine  15  48.80  
(catheterization)  Placebo  14  40.50  
MAP Clonidine  15  80.07  
(baseline)  Placebo  14  74.00  
MPAP, mean pulmonary artery pressure; MAP, mean arterial pressure.
* Descriptive level of probability of Student’s t-test.y test.
p  <  0.001),  T2  (p  <  0.001),  and  T3  (p  <  0.001).  T1  did  not  dif-
er signiﬁcantly  from  T2  (p  =  0.807)  and  T3  (p  =  0.106).  T2
iffered signiﬁcantly  from  T3  (p  <  0.001)  (Fig.  3).
In the  following  analyses,  the  study  of  drugs  used  is  pre-
ented.Table 7  shows  the  comparison  of  groups  regarding  the
volution of  sodium  nitroprusside.
The  nonparametric  Friedman’s  test  revealed  that  there
as signiﬁcant  change  in  nitroprusside  dosage  in  the
SD  Median  Min  Max  p*
17.94  44  28  100  0.200
15.93  35.5  26  77
16.29  79  59  125  0.315
15.58  72  52  100
44  B.B.  João  et  al.
Table  4  Evolution  of  MAP  according  to  study  group.
Group  Time  n  Mean  SD  Min  Max
T0  15  68.93  9.32  52  80
Clonidine  T1  15  59.00  7.22  50  79
T2 15  71.47  7.92  58  80
T3 15  64.73  7.62  51  80
T0 14  69.93  9.61  56  81
Placebo  T1  14  64.93  8.18  53  77
T2 14  74.93  7.80  59  92
T3 14  68.71  6.14  60  79
Table  5  Evolution  of  heart  rate  according  to  study  group.
Group  Time  n  Mean  SD  Min  Max
T0  15  90.07 27.65 61  145
Clonidine  T1  15  81.60 25.13  55  143
T2 15  97.93 15.29 68  122
T3 15  97.73  18.45  63  128
T0 14  88.43  23.41  49  130
Placebo  T1  14  86.50  19.22  60  125
T2 14  97.79  16.56  61  121
94.
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lonidine  (p  <  0.001)  and  placebo  (p  <  0.001)  groups.  In  cloni-
ine and  placebo  groups,  T2  differed  signiﬁcantly  from  T0
p < 0.05)  and  T1  (p  <  0.05),  with  signiﬁcantly  higher  value;
ther comparisons  showed  no  signiﬁcant  difference.
Nonparametric  Mann--Whitney  test  showed  that  the
roups did  not  differ  regarding  nitroprusside  at  T0  (=0.901),
2 (=0.138),  and  T3  (=0.147).  The  groups  differed  at  T1
a
s
(
Table  6  Evolution  of  MAP  according  to  study  group.
Group  Time  n  Mean
T0  15  38.40
Clonidine  T1  15  30.93
T2  15  28.80
T3  15  25.47
T0  14  31.36
Placebo  T1  14  24.50
T2  14  27.64
T3  14  22.86
Table  7  Evolution  of  sodium  nitroprusside  according  to  study  gro
Group  Time  n  Mean  
T0  15  0.16  
Clonidine  T1  15  0.01  
T2 15  0.90  
T3 15  0.48  
T0 14  0.19  
Placebo  T1  14  0.25  
T2 14  1.27  
T3 14  0.79  07  16.87  60  123
=0.022),  when  the  clonidine  group  showed  a  signiﬁcantly
ower value  compared  to  placebo.
Table  8  shows  the  comparison  of  groups  regarding  dobut-
mine evolution.
Nonparametric Friedman  test  revealed  that  there  was
igniﬁcant change  in  dobutamine  dosage  in  clonidine
p <  0.001)  and  placebo  groups  (p  <  0.001).  In  clonidine  and
 SD  Min  Max
 13.02  36.00  26.00
 19.16  24.00  18.00
 11.03  27.00  11.00
 7.98  25.00  11.00
 5.09  31.00  25.00
 7.55  25.00  12.00
 8.16  27.50  19.00
 5.60  22.00  10.00
up.
SD  Min  Max  Group
0.23  0.00  0.00  0.64
0.05  0.00  0.00  0.21
0.55  0.75  0.00  2.10
0.62  0.24  0.00  2.10
0.32  0.00  0.00  1.00
0.39  0.00  0.00  1.29
0.84  1.05  0.00  3.40
0.66  0.63  0.00  2.10
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Table  8  Evolution  of  dobutamine  according  to  study  group.
Group  Time  n  Mean  SD  Min  Max  Group
T0  15  0.33  1.29  0  0  5
Clonidine  T1  15  2.00  2.54  0  0  5
T2 15  5.00  1.89  5  0  10
T3 15  5.67  1.76  5  5  10
T0 14  0.00  0.00  0  0  0
Placebo  T1  14  0.36  1.34  0  0  5
T2 14  5.00  0.00  5  5  5
Table  9  Total  dose  of  fentanyl  according  to  study  group.
Group  n  Mean  SD  Min  Max  Mean  p*
Clonidine  15  19.33  4.17  20  10  25  0.208
Placebo  14  21.43 4.57  20  15  30
* Descriptive level of probability of Student’s t-test.
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placebo  groups,  T0  and  T1  differed  signiﬁcantly  from  T2
(p <  0.05)  and  T3  (p  <  0.05)  and  had  signiﬁcantly  lower  val-
ues. Other  comparisons  showed  no  signiﬁcant  difference.
Nonparametric  Mann--Whitney  test  showed  no  difference
between groups  in  relation  to  dobutamine  at  T0  (p  =  0.370),
T2 (p  =  1.000),  and  T3  (p  =  0.180).  There  was  difference
between groups  at  T1  (p  =  0.045),  with  a  signiﬁcantly  higher
value for  clonidine  compared  to  placebo.
Table  9  shows  the  comparison  of  groups  regarding  total
fentanyl, and  it  was  observed  that  there  was  no  signiﬁcant
difference between  groups  regarding  total  dose  of  fentanyl.
Discussion
Pulmonary  hypertension  associated  with  left  heart  diseases
has the  same  pathophysiological  processes  of  other  forms
of the  disease.  Early  in  the  development  of  PH,  hypoxic
vasoconstriction that,  a  priori,  is  a  reversible  physiological
mechanism becomes  constant  and  difﬁcult  to  reverse.12Unlike  what  happens  in  physiological  conditions,  endoge-
nous vasodilators,  such  as  nitric  oxide  and  prostacyclin,  are
unable to  balance  the  effects  of  mediators  responsible  for
vasoconstriction, such  as  thromboxane  A2,  endothelin,  and
a
c
berotonin.  Vascular  remodeling  involves  the  three  coats  of
he pulmonary  bed  arteries  and  consists  of  intimal  hyperpla-
ia, medial  hypertrophy,  and  proliferation  of  adventitious.13
In  situ  thrombosis  results  from  change  in  ﬂow  pattern,
hich becomes  slower;  changes  in  the  endothelium;14 and
ncreased platelet  activity  by  increased  activity  of  throm-
oxane A2.13
Patients  with  group  II  pulmonary  venous  hypertension
xhibit ventricular  dysfunction  (on  the  left)  secondary  to
alvular heart  disease  and  ischemic  cardiomyopathy  (on  the
ight) by  pressure  overload.2 Hypotension  is  part  of  this  com-
lex picture.  Pulmonary  resistance  precludes  the  passage  of
lood and  limits  the  left  ventricle  ﬁlling.  Therefore,  stroke
olume, cardiac  output,  and  blood  pressure  are  reduced.
PH  causes  hypoxemia  and  hypercapnia,  which  in  a  vicious
ircle aggravate  pulmonary  vasoconstriction.  Metabolic
cidosis and  nociceptive  stimulation,  common  events  during
nesthesia, may  also  accentuate  the  PH.
For  the  reasons  cited  above,  pharmacological  interven-
ion is  mandatory  in  these  patients  perioperatively.
Clonidine,  due  to  its  action  on  locus  coeruleus,  promotes
edation and  spinal  cord  analgesia,  hence,  the  anesthesiol-
gists’ interest  in  using  it  in  the  perioperative  period.  The
ardiovascular action  of  clonidine  is  well  known.  Its  vasodila-
or activity  is  due  to  peripheral  and  central  mechanisms.
eripherally, the  activation  of  2-adrenergic  receptors  on
resynaptic nerve  terminals  inhibits  noradrenaline  exocy-
osis, which  partially  explains  the  hypotensive  effect.  At
entral level,  it  acts  on  the  vasomotor  center  2-receptors  in
he nucleus  of  the  solitary  tract,  decreases  sympathetic  out-
ow, with  potentiation  of  parasympathetic  nervous  activity,
nd leads  to  reduced  blood  pressure.6,15,16
Despite  the  presence  of  2-adrenergic  receptors  on  nerve
ndings and  other  pulmonary  structures7--9 and  the  recog-
ized central  vasodilator  effect  of  clonidine,  there  are  no
eports in  the  literature  of  the  use  of  this  drug  to  attenu-
te pulmonary  hypertension  in  PH  adult  patients  undergoing
ardiac surgery.
Clonidine could  be  a  viable  option  for  pH  control,
ecause in  addition  to  the  beneﬁts  already  mentioned,
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lonidine  is  known  to  be  safe.  Its  effects,  which  may  some-
imes interfere  with  cardiac  output,  such  as  bradycardia  or
ypotension, are  easily  reversed  with  atropine  or  vasopres-
or such  as  ephedrine.  The  cost  of  its  use  should  also  be
aken into  account  because  it  has  a  low  price  and  is  available
n most  hospitals  worldwide.
The  possibility  of  reducing  pulmonary  arterial  pressure
ith the  use  of  clonidine  may  still  allow  a  reduction  or  even
limination of  drugs  that  are  routinely  used  in  pH  and----even
hough effective  for  disease  control----are  not  without  rele-
ant undesired  side  effects.
This  is  the  case  of  dobutamine,  which  is  used  in  this
esearch to  improve  cardiac  performance  and  reduce  pul-
onary vascular  resistance  in  PH  patients.  Dobutamine  is  a
ynthetic catecholamine,  isoproterenol  derivative,  adopted
n our  service  and  widely  used  worldwide  for  treating  PH
atients undergoing  heart  surgery.9 It  can  be  administered
lone or  in  combination  with  other  drugs.  Dobutamine  is  a  -
drenergic agent  with  predominant  action  on  1-receptors,
hich increases  the  concentration  of  cyclic  adenosine
onophosphate and  leads  to  increased  cardiac  inotropy
nd chronotropy,  reducing  systemic  vascular  and  pulmonary
esistance. Dobutamine  at  a  dosage  of  5--10  g/kg/min
mproves cardiac  contractility.
Due  to  its  activity  in  2-adrenergic  receptors  and
ncreased release  of  endogenous  adenosine,  it  has  coro-
ary vasodilator  effect  (with  normofunctioning  vascular
ndothelium).17 However,  doses  higher  than  10  g/kg/min,
s it  is  often  necessary  to  achieve  the  vasodilator  effect
n pulmonary  artery  and  increase  RV  contractility  in  PH
atients, increase  cardiac  work  and  myocardial  oxygen  con-
umption. Thus,  there  is  an  imbalance  between  supply  and
onsumption of  O2,  followed  by  myocardial  ischemia.  Its
asodilator effect  may  exacerbate  systemic  hypotension
ound in  PH  patients.3
Another  drug  routinely  used  in  cardiovascular  surgery
nd also  in  this  study  is  sodium  nitroprusside.5,18 This  drug
educes right  ventricle  afterload  by  decreasing  pulmonary
ascular resistance.  Recognized  as  a  potent  vasodilator,
TP may,  even  in  recommended  therapeutic  doses,  cause
ery undesirable  side  effects.  Undesirable  effects  such
s coronary  steal,  increased  intracranial  pressure,  volume
ompensatory need,  toxicity  by  its  metabolites,  metabolic
cidosis, and  intrapulmonary  shunt  are  particularly  found  in
ardiac patients  undergoing  heart  surgery.
The  potential  effect  of  clonidine  by  lowering  pulmonary
asculature pressure  could  result  beneﬁcial  for  dose  reduc-
ion or  even  elimination  of  these  drugs.
Patients  in  this  study  underwent  heart  surgery  to  treat
heir underlying  diseases  causing  pulmonary  hypertension,
uch as  valvular  heart  disease  and  heart  failure,  with  car-
iopulmonary bypass  under  general  balanced  anesthesia.
egarding diagnostic  method  to  select  them,  we  opted  for
he right  heart  catheterization,  because  it  is  regarded  as  the
old standard  examination  for  PH  diagnosis.12
All  patients  were  ventilated  with  a  mixture  of  oxygen
nd air  (1:1)  to  avoid  low  fraction  of  inspired  oxygen,  which
ould worsen  pulmonary  hypertension,  as  we  know.  Ven-
ilation was  set  to  maintain  capnometry  between  30  and
5 mmHg  in  order  to  prevent  hypercarbia,  an  aggravating
actor for  pulmonary  hypertension.  The  gradient  of  about
 mmHg  or  less  was  considered,19 which  is  recorded  by  the
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apnometry  device  as  a  result  of  gas  that  does  not  partici-
ate in  gas  exchange  (alveolar  dead  space).
We  try  to  keep  the  same  regime  of  ﬂuid  and  blood
eplacement in  both  groups  during  surgery,  even  during  CPB
same volume  in  milliliters  per  kilogram  of  body  weight
n the  perfusate  and  control  of  hemoconcentration  in  the
resence of  perfusion).  Therewith,  we  had  no  signiﬁcant  dif-
erence regarding  water  and  blood  balance  or  urine  output
etween the  two  groups  in  the  perioperative  period.  Differ-
nces in  blood  volume  could  result  in  signiﬁcant  changes  in
ystemic and  pulmonary  arterial  pressures  and  hinder  the
eliability of  the  research.
Still on  the  method  used,  after  the  registration  of  the
rst variables  (T0)  and  the  slow  administration  of  clonidine
r placebo,  it  was  decided  to  wait  30  min  to  measure  the
ariables of  the  subsequent  time  (T1),  because  this  is  the
pproximate time  of  this  drug  latency.  We  opted  to  perform
he last  measurements  (T3)  10  min  after  protamine.  Because
his drug  is  alkaline,  it  may  release  histamine  when  injected
apidly20,21 and,  combined  with  its  ability  to  activate  the
omplement system  when  circulating  through  the  pulmonary
asculature (in  a  complex  formed  with  heparin),22 it  could
orsen PH  and  thus  alter  the  measurements  of  pulmonary
rterial pressure.
In the  present  study,  except  at  T1,  the  administration  of
lonidine was  not  associated  with  reduced  pulmonary  artery
ressure or  decreased  need  for  infusion  of  drugs  used  for
his purpose.  At  T1,  clonidine  group  received  signiﬁcantly
ower doses  of  sodium  nitroprusside  and  signiﬁcantly  higher
oses of  dobutamine.  These  differences  were  not  repeated
t other  times  and  perhaps  may  be  explained  by  the  less
ntense surgical  stimulation  in  this  phase  of  the  intervention.
t that  time,  the  surgical  team  waited  for  the  latency  time
f clonidine,  without  manipulating  patients,  before  starting
PB.
Reducing pulmonary  arterial  pressure  in  patients  with
ulmonary hypertension  of  any  disease  classiﬁcation  group
s a  difﬁcult  task.  For  this  purpose,  endothelin  antagonists
bosentan), prostacyclin  analogs  (iloprost)  or  sildenaﬁl  has
een  clinically  used.  Intraoperatively,  phosphodiesterase
nhibitors such  as  milrinone  and  inhaled  nitric  oxide  are
sed. These  options  are  not  always  able  to  reverse  the  right
entricle deterioration  by  exacerbation  of  PH  or  improve  gas
xchange.23
Therefore,  the  fact  that  there  is  no  statistically  signiﬁ-
ant difference  between  the  clonidine  and  placebo  groups
egarding pulmonary  arterial  pressure  measurements  is  not
urprising,  although  the  ability  of  this  drug  to  decrease  vas-
ular tone  is  known.  However,  it  is  surprising  that  there  was
o difference  between  the  two  groups  regarding  systemic
lood pressure,  heart  rate,  and  fentanyl  consumption.  After
ll,  among  other  effects,  the  ability  of  this  drug  to  reduce
lood pressure  and  heart  rate  is  well  established.
Similarly,  the  potential  of  clonidine  to  reduce  the  need
or anesthesia  in  cardiac  surgery  is  known.24 Perhaps  the
ositive chronotropic  activity  of  dobutamine  has  suppressed
he bradycardic  effect  of  clonidine  and  not  allowed  dif-
erence between  both  groups  with  respect  to  heart  rate.
urthermore, catecholamine  levels  are  high  during  CPB  and
emained so  even  after  aortic  declamping25--27 and  may  over-
ome the  effects  of  clonidine  on  heart  rate  and  blood
ressure.
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Thus,  it  was  necessary  to  maintain  the  opioids  dosage.
Clonidine has  a  long  half-life  (approximately  12  h).  Thus,
although there  has  been  no  reduction  in  intraoperative  PH,
one cannot  rule  out  that  the  pulmonary  vasodilatory  action
of clonidine  is  expressed  in  the  late  postoperative  period,
when the  endogenous  adrenergic  activity  is  reduced.
The  dose  of  clonidine  used  in  this  research  may  also
be questioned.  Intravenous  dosage  prescribed  by  sev-
eral authors28--30 and  in  our  everyday  practice  is  2  g/kg.
However, when  Kulka  et  al.  examined  the  clonidine
dose--response in  cardiac  surgery,  with  2,  4  or  6  g/kg  IV28
on  sympathetic-adrenal  response,  they  only  found  effective-
ness in  blocking  catecholamine  and  hemodynamic  responses
with 4  or  6  g/kg.
In fact,  higher  doses  may  be  associated  with  more  sig-
niﬁcant vasodilator  effect  on  pulmonary  artery  and  reduce
the need  for  dobutamine  and  sodium  nitroprusside.  How-
ever, high  doses  could  also  cause  (in  a  counterproductive
way) hypertension  and  worsen  PH  by  acting  on  postsynaptic
2-adrenergic  receptors  in  walls  of  the  pulmonary  arteries.31
Due  to  the  desirable  effects  reported  by  several
authors,32--34 such  as  diuretic,  reduced  tremors  with
decreased myocardial  oxygen  consumption,  and  perioper-
ative hemodynamic  stability,  among  others,  which  were  not
goals  of  our  research,  clonidine  will  continue  to  be  consid-
ered a  useful  adjuvant  for  heart  surgery.
Conclusions
The  analysis  of  data  obtained  in  this  study  allows  us  to
conclude that  in  patients  of  group  2,  with  pulmonary  hyper-
tension undergoing  cardiac  surgery,  clonidine  (2  g/kg)
administered intravenously  after  sternotomy  was  not  able
to reduce  the  pulmonary  arterial  pressure  or  reduce  or  elim-
inate the  need  for  intraoperative  dobutamine  or  sodium
nitroprusside.
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Appendix.
A  box  of  30  ampoules  with  equal  external  labels,  15  with
150 g  clonidine  in  1  mL  solution  and  15  with  1  mL  distilled
water, without  the  active  ingredient  (placebo),  was  sent  by
the Cristália  laboratory.
Ampoules  and  patients  were  randomized  by  the  labora-
tory. A  list  to  be  followed  in  numerical  order  was  sent  with
the box.  A  sealed  envelope  containing  the  clonidine  and
placebo ampoules  could  only  be  opened  at  the  end  of  the
investigation.
During the  study,  both  patients  and  the  investigator  were
blind to  the  treatment  used;  therefore,  it  was  a  controlled,
comparative, randomized  and  double-blind  study.
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